[Opiate replacement therapy in France: assessment of the public policies].
Chast
F
F
D002047:Buprenorphine / Q000009:adverse effects / Q000627:therapeutic use; D005602:France; D006291:Health Policy / Q000331:legislation & jurisprudence* / Q000639:trends*; D006801:Humans; D007883:Legislation, Medical / Q000639:trends*; D001523:Mental Disorders / Q000150:complications; D008691:Methadone / Q000009:adverse effects / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D009294:Narcotics / Q000009:adverse effects / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D019966:Substance-Related Disorders
D009292:Narcotic Antagonists; D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone